Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

117 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The "analgizer" in a general hospital: a preliminary report.
Romagnoli A, Busque L, Power DJ. Romagnoli A, et al. Among authors: busque l. Can Anaesth Soc J. 1970 May;17(3):275-8. doi: 10.1007/BF03004607. Can Anaesth Soc J. 1970. PMID: 5512851 No abstract available.
CALR mutation burden in essential thrombocythemia and disease outcome.
Guglielmelli P, Szuber N, Gangat N, Capecchi G, Maccari C, Harnois M, Karrar O, Abdelmagid M, Balliu M, Nacca E, Atanasio A, Sestini I, Désilets A, Loscocco GG, Rotunno G, Busque L, Tefferi A, Vannucchi AM. Guglielmelli P, et al. Among authors: busque l. Blood. 2024 Mar 28;143(13):1310-1314. doi: 10.1182/blood.2023023428. Blood. 2024. PMID: 38252902
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.
Garcia-Manero G, McCloskey J, Griffiths EA, Yee KWL, Zeidan AM, Al-Kali A, Deeg HJ, Patel PA, Sabloff M, Keating MM, Zhu N, Gabrail NY, Fazal S, Maly J, Odenike O, Kantarjian H, DeZern AE, O'Connell CL, Roboz GJ, Busque L, Buckstein R, Amin H, Randhawa J, Leber B, Shastri A, Dao KH, Oganesian A, Hao Y, Keer HN, Azab M, Savona MR. Garcia-Manero G, et al. Among authors: busque l. Lancet Haematol. 2024 Jan;11(1):e15-e26. doi: 10.1016/S2352-3026(23)00338-1. Lancet Haematol. 2024. PMID: 38135371 Clinical Trial.
Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment-free remission after failing the first attempt with imatinib: Treatment-free Remission Accomplished by Dasatinib (TRAD) study.
Perusini MA, Novitzky-Basso I, Atenafu EG, Forrest D, Bence-Bruckler I, Savoie L, Keating MM, Busque L, Delage R, Xenocostas A, Liew E, Laneuville P, Paulson K, Stockley T, Lipton JH, Leber B, Kim DDH. Perusini MA, et al. Among authors: busque l. Br J Haematol. 2023 Dec;203(5):781-791. doi: 10.1111/bjh.19058. Epub 2023 Sep 11. Br J Haematol. 2023. PMID: 37697469
Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy.
Khadadah FM, Cerquozzi S, Olney HJ, Fraga C, Dudebout J, Xenocostas A, Finn N, Ethier V, Savoie ML, Busque L, Jamani K, Kuruvilla P, Faught C, Leber B, Kaedbey R, Assouline SE, Kim D. Khadadah FM, et al. Among authors: busque l. Leuk Res. 2023 Oct;133:107374. doi: 10.1016/j.leukres.2023.107374. Epub 2023 Aug 22. Leuk Res. 2023. PMID: 37657146
Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR-PRO study.
Zambrotta GPM, Nicolini FE, Assouline S, Busque L, Pungolino E, Abruzzese E, Miggiano MC, Elena C, Alvarez-Larran A, Triguero A, Iurlo A, Bucelli C, Cerrano M, Capodanno I, Lunghi F, le Coutre P, Galimberti S, Caocci G, Maffioli M, Stagno F, Saussele S, Piazza R, Druker BJ, Fava C, Guglielmana V, Colombo F, Antolini L, Gambacorti-Passerini C. Zambrotta GPM, et al. Among authors: busque l. Am J Hematol. 2023 Nov;98(11):1762-1771. doi: 10.1002/ajh.27073. Epub 2023 Aug 30. Am J Hematol. 2023. PMID: 37647134
117 results